Lead Product(s) : EVX-V1
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Evaxion Reports Positive Preclinical Data for Cytomegalovirus Vaccine EVX-V1
Details : EVX V1 is a next-generation vaccine against Cytomegalovirus (CMV) with broader and longer-lasting protection, being developed by Evaxion Biotech.
Product Name : EVX-V1
Product Type : Vaccine
Upfront Cash : Inapplicable
December 11, 2024
Lead Product(s) : EVX-V1
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : EVX-B2
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Preclinical
Sponsor : Merck & Co
Deal Size : $3.2 million
Deal Type : Expanded Collaboration
Evaxion significantly expands vaccine development collaboration with MSD
Details : Through the expanded collaboration, Evaxion will advance its innovative pipeline and has granted MSD the exclusive option to license vaccine candidate, EVX-B2, a protein-based treatment for Gonorrhea.
Product Name : EVX-B2
Product Type : Vaccine
Upfront Cash : Undisclosed
September 26, 2024
Lead Product(s) : EVX-B2
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Preclinical
Sponsor : Merck & Co
Deal Size : $3.2 million
Deal Type : Expanded Collaboration
Lead Product(s) : EVX-B2
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Evaxion Obtains Pre-clinical Proof-of-Concept for mRNA Gonorrhea Vaccine Candidate EVX-B2
Details : EVX-B2 is a prophylactic mRNA vaccine being developed by Evaxion Biotech for the prevention of gonorrhea. The specific immune response leads to the elimination of the gonorrhea bacteria.
Product Name : EVX-B2
Product Type : Vaccine
Upfront Cash : Inapplicable
September 09, 2024
Lead Product(s) : EVX-B2
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : EVX-B1
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Evaxion and Collaborator Announce Positive Results for EVX-B1 Vaccine for Staphylococcus.A
Details : EVX-B1, a vaccine against Staphylococcus aureus (S. aureus) containing AI-identified antigens, is highly protective & it is being evaluated for the treatment of S. aureus disease.
Product Name : EVX-B1
Product Type : Vaccine
Upfront Cash : Inapplicable
February 04, 2024
Lead Product(s) : EVX-B1
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : EVX-B2
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Preclinical
Sponsor : Afrigen Biologics and Vaccines
Deal Size : Undisclosed
Deal Type : Collaboration
Details : The collaboration aims at developing a novel, prophylactic, mRNA vaccine, EVX-B2, based on Evaxion’s EDEN™ platform, a proprietary AI platform capable of rapidly identifying those antigens that will trigger a highly protective immune response, to dis...
Product Name : EVX-B2
Product Type : Vaccine
Upfront Cash : Undisclosed
September 20, 2023
Lead Product(s) : EVX-B2
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Preclinical
Sponsor : Afrigen Biologics and Vaccines
Deal Size : Undisclosed
Deal Type : Collaboration
Lead Product(s) : EVX-B3
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Preclinical
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : EVX-B3, an AI-designed vaccine using both its EDEN™ and RAVEN™ AI platforms to identify protective antigens capable of eliciting both a humoral (antibody) and cellular response to the pathogen.
Product Name : EVX-B3
Product Type : Vaccine
Upfront Cash : Inapplicable
September 18, 2023
Lead Product(s) : EVX-B3
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Preclinical
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : EVX-B1
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Evaxion Presents Promising Results on EVX-B1, an AI-designed Vaccine Against Staphylococcus Aureus
Details : EVX-B1, a vaccine against Staphylococcus aureus (S. aureus) containing AI-identified antigens, is highly protective against S. aureus disease in preclinical animal models.
Product Name : EVX-B1
Product Type : Vaccine
Upfront Cash : Inapplicable
July 31, 2023
Lead Product(s) : EVX-B1
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : SYN002
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Preclinical
Sponsor : The Danish Growth Fund
Deal Size : $31.8 million
Deal Type : Series A Financing
Details : Synklino will advance its drug candidate SYN002 for the treatment of Cytomegalovirus (CMV), into both ex vivo and in vivo Phase 1 clinical trials and generate safety and efficacy data establishing a solid foundation.
Product Name : SYN002
Product Type : Protein
Upfront Cash : Undisclosed
August 06, 2022
Lead Product(s) : SYN002
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Preclinical
Sponsor : The Danish Growth Fund
Deal Size : $31.8 million
Deal Type : Series A Financing
Lead Product(s) : EVX-V1
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Preclinical
Sponsor : ExpreS2ion Biotechnologies
Deal Size : Undisclosed
Deal Type : Collaboration
Details : Under the terms of the collaboration, ExpreS2ion will have the exclusive right to license the EVX-V1 (CMV vaccine candidate) under a potential development and commercialization agreement.
Product Name : EVX-V1
Product Type : Vaccine
Upfront Cash : Undisclosed
June 12, 2022
Lead Product(s) : EVX-V1
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Preclinical
Sponsor : ExpreS2ion Biotechnologies
Deal Size : Undisclosed
Deal Type : Collaboration
Lead Product(s) : EVX-B2
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Preclinical
Sponsor : National Institutes of Health
Deal Size : Undisclosed
Deal Type : Funding
Evaxion Announces NIH Grant for Research Collaboration With UMass Chan Medical School
Details : In preclinical studies, the vaccine candidate EVX-B2 (multivalent gonorrhea vaccine) has demonstrated protection against infection, holding great promise for future development and the patients in need.
Product Name : EVX-B2
Product Type : Vaccine
Upfront Cash : Undisclosed
June 09, 2022
Lead Product(s) : EVX-B2
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Preclinical
Sponsor : National Institutes of Health
Deal Size : Undisclosed
Deal Type : Funding